Keloids and hypertrophic scars: Update and future directions

Plastic and Reconstructive Surgery

Volumn 1, Issue 4, 2013, Pages

  Huang, Chenyu ^a,b   Murphy, George F ^c   Akaishi, Satoshi ^a,d   Ogawa, Rei ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Meitan General Hospital   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879521008     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/GOX.0b013e31829c4597     Document Type: Article

References (62)

1. Huang C, Akaishi S, Hyakusoku H, et al. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. 2012 Nov 22. [Epub ahead of print].
2. Sahl WJ Jr, Clever H. Cutaneous scars: part I. Int J Dermatol. 1994;33:681-691.
3. Wahl SM, Wahl LM, McCarthy JB. Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol. 1978;121:942-946.
4. Simpson DM, Ross R. The neutrophilic leukocyte in wound repair a study with antineutrophil serum. J Clin Invest. 1972;51:2009-2023.
5. Clark RAF. Wound repair: overview and general consideration. In: Clar RAF, ed. The Molecular and Cellular Biology of Wound Repair. 2nd ed. New York: Plenum Press; 1996:3-50.
6. Miller MC, Nanchahal J. Advances in the modulation of cutaneous wound healing and scarring. BioDrugs 2005;19:363-381.
7. Levenson SM, Geever EF, Crowley LV, et al. The healing of rat skin wounds. Ann Surg. 1965;161:293-308.
8. Lee JY, Yang CC, Chao SC, et al. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. 2004;26:379-384.
9. Ehrlich HP, Desmoulière A, Diegelmann RF, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 1994;145:105-113.
10. Rossiello L, D'Andrea F, Grella R, et al. Differential expression of cyclooxygenases in hypertrophic scar and keloid tissues. Wound Repair Regen. 2009;17:750-757.
11. Niessen FB, Schalkwijk J, Vos H, et al. Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J Pathol. 2004;202:121-129.
12. Niessen FB, Andriessen MP, Schalkwijk J, et al. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. J Pathol. 2001;194:207-216.
13. Bagabir R, Byers RJ, Chaudhry IH, et al. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. Br J Dermatol. 2012;167:1053-1066.
14. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol. 2006;208:336-343.
15. Garner WL. Epidermal regulation of dermal fibroblast activity. Plast Reconstr Surg. 1998;102:135-139.
16. Machesney M, Tidman N, Waseem A, et al. Activated keratinocytes in the epidermis of hypertrophic scars. Am J Pathol. 1998;152:1133-1141.
17. Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: A comprehensive review. Plast Reconstr Surg. 1989;84:827-837.
18. Verhaegen PD, van Zuijlen PP, Pennings NM, et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. Wound Repair Regen. 2009;17:649-656.
19. Louw L. The keloid phenomenon: progress toward a solution. Clin Anat. 2007;20:3-14.
20. Uitto J, Perejda AJ, Abergel RP, et al. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci U S A. 1985;82:5935-5939.
21. Friedman DW, Boyd CD, Mackenzie JW, et al. Regulation of collagen gene expression in keloids and hypertrophic scars. J Surg Res. 1993;55:214-222.
22. Abergel RP, Pizzurro D, Meeker CA, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol. 1985;84:384-390.
23. Ghahary A, Shen YJ, Nedelec B, et al. Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J Invest Dermatol. 1996;106:476-481.
24. Clark JA, Turner ML, Howard L, et al. Description of familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity. BMC Dermatol. 2009;9:8.
25. Bertheim U, Hellström S. The distribution of hyaluronan in human skin and mature, hypertrophic and keloid scars. Br J Plast Surg. 1994;47:483-489.
26. Nagata H, Ueki H, Moriguchi T. Fibronectin. Localization in normal human skin, granulation tissue, hypertrophic scar, mature scar, progressive systemic sclerotic skin, and other fibrosing dermatoses. Arch Dermatol. 1985;121:995-999.
27. Kischer CW, Hendrix MJ. Fibronectin (FN) in hypertrophic scars and keloids. Cell Tissue Res. 1983;231:29-37.
28. Nakaoka H, Miyauchi S, Miki Y. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars. Acta Derm Venereol. 1995;75:102-104.
29. Lu F, Gao J, Ogawa R, et al. Fas-mediated apoptotic signal transduction in keloid and hypertrophic scar. Plast Reconstr Surg. 2007;119:1714-1721.
30. Aarabi S, Bhatt KA, Shi Y, et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J. 2007;21:3250-3261.
31. Ong CT, Khoo YT, Mukhopadhyay A, et al. Comparative proteomic analysis between normal skin and keloid scar. Br J Dermatol. 2010;162:1302-1315.
32. Cohen IK, Beaven MA, Horáková Z, et al. Histamine and collagen synthesis in keloid and hypertrophic scar. Surg Forum. 1972;23:509-510.
33. Smith CJ, Smith JC, Finn MC. The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. J Burn Care Rehabil. 1987;8:126-131.
34. Gruber BL, Kew RR, Jelaska A, et al. Human mast cells activate fibroblasts: Tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol. 1997;158:2310-2317.
35. Kofford MW, Schwartz LB, Schechter NM, et al. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-Terminal propeptide. J Biol Chem. 1997;272:7127-7131.
36. Yamamoto T, Hartmann K, Eckes B, et al. Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. J Dermatol Sci. 2001;26:106-111.
37. Moyer KE, Saggers GC, Ehrlich HP. Mast cells promote fibroblast populated collagen lattice contraction through gap junction intercellular communication. Wound Repair Regen. 2004;12:269-275.
38. Pistorio AL, Ehrlich HP. Modulatory effects of connexin-43 expression on gap junction intercellular communications with mast cells and fibroblasts. J Cell Biochem. 2011;112:1441-1449.
39. Gallant-Behm CL, Hildebrand KA, Hart DA. The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs. Wound Repair Regen. 2008;16:226-233.
40. Marneros AG, Norris JE, Watanabe S, et al. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol. 2004;122:1126-1132.
41. Chen Y, Gao JH, Yan X, et al. [Location of predisposing gene for one Han Chinese keloid pedigree]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2007;23:137-140.
42. Nakashima M, Chung S, Takahashi A, et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet. 2010;42:768-771.
43. Ogawa R, Okai K, Tokumura F, et al. The relationship between skin stretching/contraction and pathologic scarring: The important role of mechanical forces in keloid generation. Wound Repair Regen. 2012;20:149-157.
44. Ogawa R. Keloid and hypertrophic scarring may result from a mechanoreceptor or mechanosensitive nociceptor disorder. Med Hypotheses 2008;71:493-500.
45. Louw L. Keloids in rural black South Africans. Part 1: general overview and essential fatty acid hypotheses for keloid formation and prevention. Prostaglandins Leukot Essent Fatty Acids 2000;63:237-245.
46. Akaishi S, Akimoto M, Ogawa R, et al. The relationship between keloid growth pattern and stretching tension: visual analysis using the finite element method. Ann Plast Surg. 2008;60:445-451.
47. Huang C, Akaishi S, Ogawa R. Mechanosignaling pathways in cutaneous scarring. Arch Dermatol Res. 2012;304:589-597.
48. Fong EP, Bay BH. Keloids-The sebum hypothesis revisited. Med Hypotheses 2002;58:264-269.
49. Ueda K, Furuya E, Yasuda Y, et al. Keloids have continuous high metabolic activity. Plast Reconstr Surg. 1999;104:694-698.
50. Ichioka S, Ando T, Shibata M, et al. Oxygen consumption of keloids and hypertrophic scars. Ann Plast Surg. 2008;60:194-197.
51. Arima J, Ogawa R, Iimura T, et al. Relationship between keloid and hypertension. J Nippon Med Sch. 2012;79:494-495.
52. Ogawa R, Arima J, Ono S, et al. Total management of a severe case of systemic keloids associated with high blood pressure (hypertension)-clinical symptoms of keloids may be aggravated by hypertension. ePlasty 2013;13:e25.
53. Janssen de Limpens AM, Cormane RH. Studies on the immunologic aspects of keloids and hypertrophic scars. Arch Dermatol Res. 1982;274:259-266.
54. Aggarwal H, Saxena A, Lubana PS, et al. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol. 2008;7:43-49.
55. Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg. 2012;38:104-109.
56. Huang C, Ono S, Hyakusoku H, et al. Small-wave incision method for linear hypertrophic scar reconstruction: A parallel-group randomized controlled study. Aesthetic Plast Surg. 2012;36:387-395.
57. Ogawa R, Akaishi S, Huang C, et al. Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: The importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction. J Nippon Med Sch. 2011;78:68-76.
58. Akaishi S, Akimoto M, Hyakusoku H, et al. The tensile reduction effects of silicone gel sheeting. Plast Reconstr Surg. 2010;126:109e-111e.
59. Louw L. Keloids in rural black South Africans. Part 3: A lipid model for the prevention and treatment of keloid formations. Prostaglandins Leukot Essent Fatty Acids 2000;63:255-262.
60. Martin-García RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg. 2005;31(11, Part 1):1394-1398.
61. Moon JH, Kwak SS, Park G, et al. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem Cells Dev. 2008;17:713-724.
62. Akino K, Akita S, Yakabe A, et al. Human mesenchymal stem cells may be involved in keloid pathogenesis. Int J Dermatol. 2008;47:1112-1117.